634 656
Table 1 – Descriptive statistics of 681 patients with clinically localized prostate cancer (PCa) treated with radical prostatectomy and
extended pelvic lymph node dissection between 2011 and 2016
Overall
pN0
pN1
p
value
(
n
= 681)
(
n
= 602, 88%)
(
n
= 79, 12%)
Year of surgery
Median (IQR)
2014 (2013–2015)
2014 (2013–2015)
2014 (2013–2015)
0.1
Age at surgery (yr)
Median (IQR)
65 (60–70)
65 (60–70)
65 (59–71)
0.9
Preoperative PSA (ng/ml)
Median (IQR)
6.2 (4.6–8.3)
6.0 (4.5–7.9)
10.8 (6.1–21)
<
0.001
Clinical stage (%)
T1
375 (55)
357 (59)
18 (23)
<
0.001
T2
264 (39)
222 (37)
42 (53)
T3
42 (6.2)
23 (3.8)
19 (24)
Biopsy Gleason grade group (%)
1
261 (38)
260 (43)
1 (1.3)
<
0.001
2
247 (37)
233 (39)
14 (18)
3
93 (14)
65 (11)
28 (35)
4
48 (7.0)
33 (5.5)
15 (19)
5
32 (4.7)
11 (1.8)
21 (27)
No. of cores taken
Median (IQR)
14 (12–20)
14 (12–20)
14 (12–18)
0.4
Percentage of positive cores
Median (IQR)
33.3 (14.7–50.0)
31.6 (14.3–50.0)
62.5 (42.8–85.7)
<
0.001
Percentage of positive cores with highest-grade PCa
Median (IQR)
29.4 (14.3–50.0)
25.0 (13.2–45.0)
50.0 (31.9–81.8)
<
0.001
Percentage of positive cores with lower grade PCa
aMedian (IQR)
27.7 (16.6–41.6)
25.0 (16.6–41.6)
33.3 (23.3–51.8)
0.06
Maximum percentage of single core involvement with highest-grade PCa
Median (IQR)
32.1 (11.5–70.0)
30.0 (10.0–60.0)
75.0 (40.0–90.0)
<
0.001
Maximum percentage of single core involvement with lower-grade PCa
aMedian (IQR)
41.7 (20.0–69.2)
40.9 (20.0–61.1)
76.8 (31.2–93.4)
0.02
Total tumor length (cm)
Median (IQR)
1.5 (0.4–3.6)
1.3 (0.35–2.93)
4.9 (2.6–8.9)
<
0.001
Total biopsy length (cm)
Median (IQR)
20.0 (16.4–25.9)
20.0 (16.4–26.0)
20.0 (17.1–23.4)
0.7
Percentage of tumor in biopsy cores
Median (IQR)
8.1 (1.9–18.5)
6.8 (1.7–15.8)
27.8 (11.3–45.6)
<
0.001
Tumor length of highest-grade PCa (cm)
Median (IQR)
1.3 (0.4–3.1)
1.12 (0.3–2.7)
2.0 (4.2–7.8)
<
0.001
Percentage of highest-grade PCa in biopsy cores
Median (IQR)
7.2 (1.7–16.1)
6.1 (1.6–14.3)
21.4 (10.7–40.6)
<
0.001
Tumor length of lower-grade PCa (cm)
aMedian (IQR)
1.15 (0.5–2.71)
0.9 (0.41–1.95)
2.1 (1.18–4.51)
0.2
Percentage of lower-grade PCa in biopsy cores
Median (IQR)
8.04 (3.5–15.0)
7.1 (2.9–12.5)
12.8 (8.6–36.1)
<
0.001
Surgical technique (%)
ORP
205 (30)
160 (27)
45 (57)
<
0.001
RARP
476 (70)
442 (73)
34 (43)
Gleason grade group at final pathology (%)
1
136 (20)
130 (22)
6 (7.6)
<
0.001
2
279 (41)
272 (45)
7 (8.9)
3
140 (21)
128 (21)
12 (15)
4
39 (6)
26 (4.3)
13 (17)
5
87 (13)
46 (7.6)
41 (51.9)
Pathologic stage (%)
T2
427 (63)
423 (71)
4 (5.1)
<
0.001
T3a
179 (26)
153 (26)
26 (32.9)
T3b/4
73 (11)
24 (4.0)
49 (62)
Positive surgical margins (%)
131 (19)
90 (15)
41 (54)
<
0.001
Number of removed lymph nodes
Median (IQR)
16 (8–22)
15 (8–21)
20 (15–27)
0.1
Number of positive lymph nodes
Median (IQR)
0 (0)
0 (0)
2 (1–4)
NA
Site of LNI (%)
Obturator fossa
–
–
42 (53)
NA
Internal iliac region
–
–
20 (25)
External iliac region
–
–
34 (43)
Common iliac region
–
–
9 (11)
Presacral area
–
–
7 (8.9)
IQR = interquartile range; LNI = lymph node invasion; NA = not applicable; ORP = open radical prostatectomy; PSA = prostate-specific antigen; RARP = robot-
assisted radical prostatectomy.
a
In patients with two or more lesions with different grades (
n
= 81).
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 3 2 – 6 4 0
634